AAPL299.23+1.22 (+0.41%) ▲|ABBV229.90+13.41 (+6.19%) ▲|ABT88.22-0.19 (-0.21%) ▼|ACN119.17-8.82 (-6.89%) ▼|ADBE192.21-2.95 (-1.51%) ▼|AMAT622.55+5.44 (+0.88%) ▲|AMD545.39+8.02 (+1.49%) ▲|AMGN343.49+5.89 (+1.74%) ▲|AMT176.87+0.82 (+0.47%) ▲|AMZN234.41-9.99 (-4.09%) ▼|AVGO394.63-16.72 (-4.06%) ▼|AXP336.49-1.51 (-0.45%) ▼|BA220.85-1.87 (-0.84%) ▼|BAC57.32+1.12 (+1.98%) ▲|BKNG167.98-3.80 (-2.21%) ▼|BLK1,046.72-3.38 (-0.32%) ▼|BMY54.41+0.41 (+0.75%) ▲|BNY145.86+2.23 (+1.55%) ▲|BRK-B489.03-0.43 (-0.09%) ▼|C145.35+2.29 (+1.60%) ▲|CAT1,017.74+31.92 (+3.24%) ▲|CL89.69+0.21 (+0.23%) ▲|CMCSA22.40-0.04 (-0.16%) ▼|COF200.90-0.64 (-0.32%) ▼|COP109.38+1.64 (+1.52%) ▲|COST948.42-3.03 (-0.32%) ▼|CRM149.11-2.67 (-1.76%) ▼|CSCO121.19+1.65 (+1.38%) ▲|CVS101.85+3.53 (+3.59%) ▲|CVX175.00+1.37 (+0.79%) ▲|DE596.83+7.59 (+1.29%) ▲|DHR177.81+0.64 (+0.36%) ▲|DIS101.91-1.99 (-1.91%) ▼|DUK124.26+0.40 (+0.32%) ▲|EMR149.71-0.95 (-0.63%) ▼|FDX327.69+2.71 (+0.83%) ▲|GD343.06-6.95 (-1.99%) ▼|GE357.43-0.21 (-0.06%) ▼|GEV1,126.04+16.31 (+1.47%) ▲|GILD124.53+0.77 (+0.62%) ▲|GM80.88+1.59 (+2.01%) ▲|GOOG347.18-20.28 (-5.52%) ▼|GOOGL347.82-20.21 (-5.49%) ▼|GS1,098.72+2.16 (+0.20%) ▲|HD326.72-7.56 (-2.26%) ▼|HON228.36-0.66 (-0.29%) ▼|IBM246.50-2.60 (-1.04%) ▼|INTC140.81+6.82 (+5.09%) ▲|INTU256.53-10.47 (-3.92%) ▼|ISRG401.95-4.83 (-1.19%) ▼|JNJ230.40+2.01 (+0.88%) ▲|JPM331.90+6.68 (+2.05%) ▲|KO79.84+0.45 (+0.57%) ▲|LIN514.18+2.03 (+0.40%) ▲|LLY1,104.38+5.81 (+0.53%) ▲|LMT492.33-18.62 (-3.64%) ▼|LOW214.13-8.07 (-3.63%) ▼|LRCX395.18+6.14 (+1.58%) ▲|MA483.72-6.07 (-1.24%) ▼|MCD270.80-7.82 (-2.81%) ▼|MDLZ59.85-0.27 (-0.45%) ▼|MDT79.17-0.17 (-0.21%) ▼|META565.20-12.02 (-2.08%) ▼|MMM162.45+1.85 (+1.15%) ▲|MO69.65+0.53 (+0.76%) ▲|MRK114.75+0.88 (+0.77%) ▲|MS227.19+4.02 (+1.80%) ▲|MSFT370.13-9.27 (-2.44%) ▼|MU1,194.66+60.67 (+5.35%) ▲|NEE86.60-0.16 (-0.18%) ▼|NFLX72.86-4.52 (-5.84%) ▼|NKE43.21-2.00 (-4.41%) ▼|NOW92.05-2.99 (-3.15%) ▼|NVDA208.65-2.04 (-0.97%) ▼|ORCL175.26-9.04 (-4.90%) ▼|PEP140.70-1.33 (-0.93%) ▼|PFE25.01-0.21 (-0.81%) ▼|PG148.80-1.58 (-1.05%) ▼|PLTR119.62-8.86 (-6.89%) ▼|PM173.53-4.87 (-2.73%) ▼|QCOM222.21-3.90 (-1.72%) ▼|RTX182.46-3.14 (-1.69%) ▼|SBUX100.00-0.65 (-0.65%) ▼|SCHW92.03+0.33 (+0.35%) ▲|SO93.86+0.77 (+0.82%) ▲|SPG213.67+2.34 (+1.11%) ▲|T22.17+0.16 (+0.70%) ▲|TMO461.89-2.72 (-0.59%) ▼|TMUS181.05-0.62 (-0.34%) ▼|TSLA405.86+5.37 (+1.34%) ▲|TXN328.55+5.69 (+1.76%) ▲|UBER71.74+0.10 (+0.14%) ▲|UNH408.36+7.40 (+1.84%) ▲|UNP259.79+2.91 (+1.13%) ▲|UPS107.50+2.64 (+2.52%) ▲|USB58.58+0.44 (+0.75%) ▲|V326.67-0.57 (-0.17%) ▼|VZ45.41+0.04 (+0.09%) ▲|WFC83.81+1.61 (+1.95%) ▲|WMT117.20+0.02 (+0.02%) ▲|XOM138.48+0.67 (+0.49%) ▲|AAPL299.23+1.22 (+0.41%) ▲|ABBV229.90+13.41 (+6.19%) ▲|ABT88.22-0.19 (-0.21%) ▼|ACN119.17-8.82 (-6.89%) ▼|ADBE192.21-2.95 (-1.51%) ▼|AMAT622.55+5.44 (+0.88%) ▲|AMD545.39+8.02 (+1.49%) ▲|AMGN343.49+5.89 (+1.74%) ▲|AMT176.87+0.82 (+0.47%) ▲|AMZN234.41-9.99 (-4.09%) ▼|AVGO394.63-16.72 (-4.06%) ▼|AXP336.49-1.51 (-0.45%) ▼|BA220.85-1.87 (-0.84%) ▼|BAC57.32+1.12 (+1.98%) ▲|BKNG167.98-3.80 (-2.21%) ▼|BLK1,046.72-3.38 (-0.32%) ▼|BMY54.41+0.41 (+0.75%) ▲|BNY145.86+2.23 (+1.55%) ▲|BRK-B489.03-0.43 (-0.09%) ▼|C145.35+2.29 (+1.60%) ▲|CAT1,017.74+31.92 (+3.24%) ▲|CL89.69+0.21 (+0.23%) ▲|CMCSA22.40-0.04 (-0.16%) ▼|COF200.90-0.64 (-0.32%) ▼|COP109.38+1.64 (+1.52%) ▲|COST948.42-3.03 (-0.32%) ▼|CRM149.11-2.67 (-1.76%) ▼|CSCO121.19+1.65 (+1.38%) ▲|CVS101.85+3.53 (+3.59%) ▲|CVX175.00+1.37 (+0.79%) ▲|DE596.83+7.59 (+1.29%) ▲|DHR177.81+0.64 (+0.36%) ▲|DIS101.91-1.99 (-1.91%) ▼|DUK124.26+0.40 (+0.32%) ▲|EMR149.71-0.95 (-0.63%) ▼|FDX327.69+2.71 (+0.83%) ▲|GD343.06-6.95 (-1.99%) ▼|GE357.43-0.21 (-0.06%) ▼|GEV1,126.04+16.31 (+1.47%) ▲|GILD124.53+0.77 (+0.62%) ▲|GM80.88+1.59 (+2.01%) ▲|GOOG347.18-20.28 (-5.52%) ▼|GOOGL347.82-20.21 (-5.49%) ▼|GS1,098.72+2.16 (+0.20%) ▲|HD326.72-7.56 (-2.26%) ▼|HON228.36-0.66 (-0.29%) ▼|IBM246.50-2.60 (-1.04%) ▼|INTC140.81+6.82 (+5.09%) ▲|INTU256.53-10.47 (-3.92%) ▼|ISRG401.95-4.83 (-1.19%) ▼|JNJ230.40+2.01 (+0.88%) ▲|JPM331.90+6.68 (+2.05%) ▲|KO79.84+0.45 (+0.57%) ▲|LIN514.18+2.03 (+0.40%) ▲|LLY1,104.38+5.81 (+0.53%) ▲|LMT492.33-18.62 (-3.64%) ▼|LOW214.13-8.07 (-3.63%) ▼|LRCX395.18+6.14 (+1.58%) ▲|MA483.72-6.07 (-1.24%) ▼|MCD270.80-7.82 (-2.81%) ▼|MDLZ59.85-0.27 (-0.45%) ▼|MDT79.17-0.17 (-0.21%) ▼|META565.20-12.02 (-2.08%) ▼|MMM162.45+1.85 (+1.15%) ▲|MO69.65+0.53 (+0.76%) ▲|MRK114.75+0.88 (+0.77%) ▲|MS227.19+4.02 (+1.80%) ▲|MSFT370.13-9.27 (-2.44%) ▼|MU1,194.66+60.67 (+5.35%) ▲|NEE86.60-0.16 (-0.18%) ▼|NFLX72.86-4.52 (-5.84%) ▼|NKE43.21-2.00 (-4.41%) ▼|NOW92.05-2.99 (-3.15%) ▼|NVDA208.65-2.04 (-0.97%) ▼|ORCL175.26-9.04 (-4.90%) ▼|PEP140.70-1.33 (-0.93%) ▼|PFE25.01-0.21 (-0.81%) ▼|PG148.80-1.58 (-1.05%) ▼|PLTR119.62-8.86 (-6.89%) ▼|PM173.53-4.87 (-2.73%) ▼|QCOM222.21-3.90 (-1.72%) ▼|RTX182.46-3.14 (-1.69%) ▼|SBUX100.00-0.65 (-0.65%) ▼|SCHW92.03+0.33 (+0.35%) ▲|SO93.86+0.77 (+0.82%) ▲|SPG213.67+2.34 (+1.11%) ▲|T22.17+0.16 (+0.70%) ▲|TMO461.89-2.72 (-0.59%) ▼|TMUS181.05-0.62 (-0.34%) ▼|TSLA405.86+5.37 (+1.34%) ▲|TXN328.55+5.69 (+1.76%) ▲|UBER71.74+0.10 (+0.14%) ▲|UNH408.36+7.40 (+1.84%) ▲|UNP259.79+2.91 (+1.13%) ▲|UPS107.50+2.64 (+2.52%) ▲|USB58.58+0.44 (+0.75%) ▲|V326.67-0.57 (-0.17%) ▼|VZ45.41+0.04 (+0.09%) ▲|WFC83.81+1.61 (+1.95%) ▲|WMT117.20+0.02 (+0.02%) ▲|XOM138.48+0.67 (+0.49%) ▲|
22.6 C
New York
Monday, June 22, 2026

Tag: pain

newssourceFORcompanyinformationcontent1marketreleases

Nova Ukraine Earns 2025 Platinum Seal of Transparency from Candid

SAN FRANCISCO, July 3, 2025 /PRNewswire/ -- Nova Ukraine is proud to announce a new milestone: Platinum Seal of Transparency from Candid. This is the highest...

Advancing Bone Health: European Commission Approves Biocon Biologics’ Denosumab Biosimilars

BENGALURU, India, July 3, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that...

Karolinska Development receives update from Organon concerning OG-6219

STOCKHOLM, SWEDEN – July 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces an update from Organon on the development of the drug candidate OG-6219, acquired by Organon through its acquisition of Forendo Pharma in 2021. Following results from a Phase 2 clinical study with OG-6219, Organon plans to discontinue the clinical development of the drug candidate.

Arthro MD+ Joint Relief Cream Officially Launches: Natural Fast-Acting Solution in US, CA, UK, AU, NZ and IE

Arthro MD Cream launches in the US, Canada, UK, Australia, and Ireland, offering a science-backed, natural solution for joint pain and mobility. Fast-acting, non-greasy formula for seniors, athletes, and more. 
Arthro MD Cream launches in the US, Canada, UK, Australia, and Ireland, offering a science-backed, natural solution for joint pain and mobility. Fast-acting, non-greasy formula for seniors, athletes, and more.

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer 

Webexpenses launch Expense Cards setting new standards for seamless spend management

From purchase to pay, an all-in-one platform to enhance control that's free for all Webexpenses users. LONDON, July 2, 2025 /PRNewswire/ -- Webexpenses, a leading...

PXPay Plus Teams Up with foodpanda to Launch Taiwan’s First Integration of Electronic Payment and Food Delivery

A New Delivery Payment Ecosystem for All Ages and Scenarios — Enjoy Up to 10% Rewards for the Launch! TAIPEI, July 1, 2025 /PRNewswire/ --...

BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate

Ad hoc announcement pursuant to Art. 53 LR

T-Pain and Clinton Sparks Officially Launch the Global Gaming League in Las Vegas

The Star-Studded Kickoff Event Hosted by Nick Cannon and Jermaine Dupri featured a Performance by Social Media Pioneer Soulja Boy 
 The Star-Studded Kickoff Event Hosted by Nick Cannon and Jermaine Dupri featured a Performance by Social Media Pioneer Soulja Boy

Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

– Conditional approval based on positive results from the HERIZON-BTC-01 Phase 2b trial – DUBLIN, July 1, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ)...

Implantica announces publication of the landmark RefluxStop® 5-year clinical study results demonstrating excellent long-term success

VADUZ, Liechtenstein, July 1, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of treatment for acid reflux with its unique device...

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation.

GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion...

The GPCR-targeting therapies market is expected to grow significantly in the coming years. This is due to the increasing number of patients who are...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPain

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers